Luzsana

SHR-8735 Clin3 chemo-induced thrombocytopenia; SHR-3162/Fuzuloparib Clin3 prostate cancer; SHR-3680 Clin3 prostate cancer; INS068 Clin2 diabetes (1&2); SHR-A1811 Clin1 so;id tumors; undisclosed Clin1 solid tumors; HRS-4800 Clin0 chemo-induced peripheral neuropathy; 3 undisclosed programs RD/Clin0 solid tumors

Luzsana Biotechnology is a global biopharmaceutical company focused on delivering innovative medicines to patients worldwide. Their mission is to make healthcare more human by ensuring that innovative medicines are available, accessible, and affordable for everyone. Luzsana’s pipeline features a variety of assets with groundbreaking mechanisms of action, targeting diseases that are notoriously difficult to treat. These include conditions with low survival rates, limited treatment options, and exorbitant costs. Luzsana has a strong pipeline of oncology drugs, including camrelizumab, a PD-1 inhibitor, and rivoceranib, a tyrosine kinase inhibitor. Their pipeline includes therapeutics that target a broad range of solid tumors. They are also developing drugs for other therapeutic areas, such as cardiovascular disease and metabolic disorders. Luzsana has a global footprint, with operations in multiple countries.

Jobs: